Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Transplant Proc ; 52(1): 326-332, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-31948799

RESUMO

BACKGROUND: Fungus-positive respiratory samples (FPRS) are common in the intensive Care unit (ICU) and are usually considered to correspond to colonization. The management of FPRS during the early postoperative course after lung transplantation (LT) remains unclear. The epidemiology, clinical consequences, and prognosis of FPRS were assessed in LT recipients. METHODS: Over a 6-year period, we analyzed the postoperative ICU course of 176 LT recipients with a specific focus on microbiological results of routine respiratory samples and clinical course. The outcomes during the ICU stay at day 28 and at 1 year were compared in patients with or without FPRS. Results are expressed as median and interquartile range. RESULTS: In the pretransplantation period, Candida spp were reported in 17% of patients. No routine post-LT antifungal prophylaxis was initiated. In the post-LT period, at least 1 FPRS was observed in 69% of patients (93% Candida spp, 7% Aspergillus spp). Double LT (odds ratio = 4.15, 95% confidence interval [1.67-11.80], P = .0007) was the only risk factor associated with Candida spp in respiratory samples. Antifungal therapy was administered in 58% of patients with post-LT Candida-positive samples. Candida spp in post-LT respiratory samples were not associated with increased ICU, 28-day, or 1-year mortality rates. CONCLUSION: A high prevalence of FPRS is reported after LT, mainly with Candida spp. The lack of association between post-LT FPRS and mortality and morbidity suggests avoiding antifungal therapy in the absence of clinical signs of invasive infection.


Assuntos
Transplante de Pulmão , Micoses/epidemiologia , Micoses/etiologia , Complicações Pós-Operatórias/epidemiologia , Complicações Pós-Operatórias/microbiologia , Candida , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Razão de Chances , Prevalência , Prognóstico , Sistema Respiratório/microbiologia , Fatores de Risco
2.
Ann Pharm Fr ; 75(4): 285-293, 2017 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-28454759

RESUMO

OBJECTIVES: No recommendations are currently available to help the clinician with the pharmacological management of intensive care unit (ICU) patients with elevated cardiac troponin (cTn) not linked to type 1 AMI. The aim of this study was to evaluate the pattern of cardiologic medications for patients with elevated cTnI in ICU not link to type 1 AMI and their effects on in-hospital mortality. MATERIAL AND METHODS: A prospective observational cohort study conducted in two ICU units. Patients with increased plasma concentration of cTnI at admission not linked to type 1 AMI were consecutively included. RESULTS: One hundred and ninety of the 835 patients admitted (23%) had an increased plasma concentration of cTnI not related to type 1 AMI. Antiplatelet therapy (AT) and statin were prescribed in 56 (29.5%) and 50 (26.3%) of patients, respectively. Others cardiologic medications were prescribed in less than 5% of all cases and were considered as contraindicated in more than 50% of cases. Antiplatelet therapy was the only cardiologic treatment associated with reduction of in-hospital mortality following uni- and multivariate analysis. The death rate was 23% and 40% in these patients treated with and without AT, respectively (aOR=0.39 [95% CI: 0.15-0.97]). CONCLUSIONS: Statin and AT were frequently prescribed to patients with a cTnI elevation not linked to type 1 AMI. This study suggests that AT in patients with an increased plasma concentration of cTnI, not related to type 1 AMI in ICU, could reduce in-hospital mortality.


Assuntos
Estado Terminal/mortalidade , Mortalidade Hospitalar , Unidades de Terapia Intensiva , Troponina I/sangue , Biomarcadores/sangue , Humanos , Infarto do Miocárdio/sangue , Estudos Prospectivos
3.
Transpl Infect Dis ; 18(1): 22-30, 2016 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-26455730

RESUMO

BACKGROUND: Multidrug-resistant (MDR) bacteria are a growing concern worldwide. The aim of this study was to describe the epidemiology and risk factors of MDR bacteria detected in respiratory invasive samples during hospitalization in the intensive care unit (ICU) after lung transplantation (LT). METHODS: This study was based on a retrospective analysis of 176 patients hospitalized in the ICU after LT in 2006-2012. Respiratory invasive samples were performed according to a routine protocol. MDR pathogens were defined according to in vitro susceptibility tests. RESULTS: A total of 1176 bacteria were cultured. Susceptibility testing was performed on 1046 strains and 404 (39%) MDR were detected in 90 (51%) patients. Pseudomonas aeruginosa, coagulase-negative staphylococci, and Enterobacteriaceae (mainly Enterobacter species) were the most common MDR pathogens. On multivariate analysis, an ICU stay >14 days, presence of a tracheostomy, and previous exposure to broad-spectrum antibiotics were associated with MDR acquisition (odds ratio [OR] 3.7; 95% confidence interval [1.69-8.12]; OR 3.28 [1.05-10.28]; and OR 2.25 [1.17-4.34], respectively). We consistently observed an increasing emergence of resistance to several antibiotics, from week 1 to week 4 of ICU hospitalization: for ticarcillin, piperacillin-tazobactam, ceftazidime, imipenem/cilastatin, amikacin, and ciprofloxacin in P. aeruginosa; and for piperacillin-tazobactam, cefepime, and amikacin in Enterobacteriaceae. CONCLUSION: A large proportion of MDR bacteria are detected on respiratory invasive samples in LT patients, and the risk of their emergence is mainly determined by the previous exposure to broad-spectrum antibiotics and the length of ICU stay. Adequate treatment requires broad-spectrum empiric antibiotic therapy.


Assuntos
Antibacterianos/uso terapêutico , Infecções Bacterianas/epidemiologia , Farmacorresistência Bacteriana Múltipla/efeitos dos fármacos , Transplante de Pulmão/efeitos adversos , Infecções Bacterianas/microbiologia , Enterobacter/efeitos dos fármacos , Enterobacteriaceae/efeitos dos fármacos , Feminino , Hospitalização , Humanos , Unidades de Terapia Intensiva , Masculino , Pessoa de Meia-Idade , Complicações Pós-Operatórias/epidemiologia , Pseudomonas aeruginosa/efeitos dos fármacos , Estudos Retrospectivos , Fatores de Risco
4.
Clin Microbiol Infect ; 21(9): 853.e1-3, 2015 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-26033667

RESUMO

Postoperative peritonitis (POP) is a common surgical complication after bariatric surgery (BS). We assessed the importance of positive fungal cultures in these cases of POP admitted to the intensive care unit. Clinical features and outcome were compared in 25 (41%) Candida-positive patients (6 (22%) fluconazole-resistant Candida glabrata) and 36 patients without Candida infection. Candida infections were more commonly isolated in late-onset peritonitis and were often associated with multidrug-resistant bacteria. Risk factors for intensive care unit mortality (19.6%) were diabetes and superobesity. Candida infections, including fluconazole-resistant strains, are common in POP after BS. These data encourage the empirical use of a broad-spectrum antifungal agent.


Assuntos
Líquido Ascítico/microbiologia , Cirurgia Bariátrica , Candida/isolamento & purificação , Candidíase/epidemiologia , Peritonite/epidemiologia , Complicações Pós-Operatórias/epidemiologia , Adulto , Bactérias/efeitos dos fármacos , Bactérias/isolamento & purificação , Candida/classificação , Candida/efeitos dos fármacos , Candidíase/microbiologia , Candidíase/mortalidade , Candidíase/patologia , Coinfecção/epidemiologia , Coinfecção/microbiologia , Coinfecção/patologia , Farmacorresistência Fúngica , Farmacorresistência Bacteriana Múltipla , Feminino , Fluconazol/farmacologia , Humanos , Masculino , Pessoa de Meia-Idade , Peritonite/microbiologia , Peritonite/mortalidade , Peritonite/patologia , Complicações Pós-Operatórias/microbiologia , Complicações Pós-Operatórias/mortalidade , Complicações Pós-Operatórias/patologia , Estudos Prospectivos , Fatores de Risco , Análise de Sobrevida
5.
Ann Fr Anesth Reanim ; 28(10): 897-9, 2009 Oct.
Artigo em Francês | MEDLINE | ID: mdl-19766437

RESUMO

Vitamin K antagonists (VKA) are very currently used. Nevertheless, they are known to interact with numerous drugs and foods. Grapefruit juice is known to interact with some drugs metabolized by the enterocytary cytochrome P450 3A4 but its interaction with drugs as VKA that have a good biodisponibility is not clearly demonstrated. We report here the case of a woman treated with VKA in whom massive absorption of grapefruit juice entailed an excessive VKA dosage and a severe haemorrhage.


Assuntos
Anticoagulantes/efeitos adversos , Anticoagulantes/metabolismo , Bebidas/efeitos adversos , Citrus paradisi/efeitos adversos , Citrus paradisi/metabolismo , Fenindiona/análogos & derivados , Vitamina K/antagonistas & inibidores , Absorção , Overdose de Drogas , Feminino , Interações Alimento-Droga , Humanos , Pessoa de Meia-Idade , Fenindiona/efeitos adversos , Fenindiona/metabolismo , Índice de Gravidade de Doença
6.
Cell Mol Biol (Noisy-le-grand) ; 51(4): 403-8, 2005 Sep 30.
Artigo em Inglês | MEDLINE | ID: mdl-16309591

RESUMO

Matrix metalloproteinases (MMPs), particularly MMP-1 and MMP-2, are involved in the pathophysiology of emphysema. MMPs contain zinc in the catalytic site and its expression is regulated transcriptionally via mitogen activated protein kinases (MAPKs). Carbon monoxide (CO), one of the end products of heme oxygenase activity, has anti-inflammatory properties, which are mediated, at least in part, by activation of p38 MAPK. Furthermore, CO has the unique ability to bind to metal centers in proteins and can affect their specific activity. Therefore, we hypothesized that CO could inhibit MMPs expression and/or activity. Here we show that a recently identified carbon monoxide-releasing molecule, [Ru(CO)3Cl2]2 (or CORM-2) inhibits MMP-1 and MMP-2 mRNA expression in the human lung epithelial cell line A549. The MMPs mRNA expression was unaffected by the p38 MAPK inhibitor SB203580, but in the case of MMP-1 was reversed by the antioxidant N-acetylcysteine. In addition, CORM-2 inhibited both MMP-1 and MMP-2 activities. Interestingly, no effect was observed with (Ru(DMSO)4Cl2), a negative control that does not contain CO groups. To the best of our knowledge this is the first evidence on the effect of CO on MMPs expression and activity. This effect could have important implications in the pathophysiology of emphysema and other diseases involving proteases/antiproteases imbalance.


Assuntos
Monóxido de Carbono/farmacologia , Células Epiteliais/efeitos dos fármacos , Células Epiteliais/enzimologia , Regulação Enzimológica da Expressão Gênica/efeitos dos fármacos , Metaloproteinase 1 da Matriz/metabolismo , Metaloproteinase 2 da Matriz/metabolismo , Alvéolos Pulmonares/citologia , Linhagem Celular Tumoral , Humanos , Interleucina-1beta/farmacologia , Metaloproteinase 1 da Matriz/genética , Metaloproteinase 2 da Matriz/genética , Compostos Organometálicos/farmacologia , RNA Mensageiro/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA